FDA will issue formal ibogaine cardiac safety guidance requiring mandatory cardiac screening protocols before any IND approval proceeds, by Q1 2027.

The FDA (the US drug regulator) will write formal rules saying anyone testing ibogaine must get heart tests first, because recent research shows ibogaine can cause dangerous heart rhythms. This matters because it slows down ibogaine research but protects people from cardiac injury.

Two ibogaine cardiac papers published same day as veteran advocacy surge creates exactly the kind of risk signal FDA cannot ignore. Scoping review plus QT arrhythmia paper together constitute sufficient safety flag to trigger formal guidance.